Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Progressive Digital Media Group PLC       GB00B1GCQP32

News SummaryMost relevantAll newsSector newsTweets

GlobalData : Hemophilia A and B market to welcome newcomers as established companies fall behind

share with twitter share with LinkedIn share with facebook
share via e-mail
07/19/2017 | 05:33pm CEST

The hemophilia A and B market, which is set to approach $8 billion by 2026, will see a substantial number of newcomers capture market share from established companies, according to research and consulting firm GlobalData.

The company's latest report states that the hemophilia market has historically been characterized by a high level of brand loyalty. Companies employ huge sales forces and invest large sums in initiatives such as college scholarships, patient communities and co-pay assistance programs with the aim of creating and maintaining a life-long relationship with patients and their families.

Chiara Marchetti, Ph.D., Healthcare Analyst for GlobalData, explains: 'Before the approval of long-acting factor concentrates, the movement of patients from established treatment options to new short-acting recombinant factors had been minimal due to the lack of any clinical incentive.

'However, GlobalData expects that the improvements in convenience offered by long-acting factors and alternative coagulation promoters will help new entrants, such as Bioverativ and Roche, to establish themselves as key players in the hemophilia market. This process had already begun for hemophilia B, where the improved prophylactic dosing schedule of long-acting clotting factor IX has undermined Pfizer's position in the US.'

Baxalta was the dominant player in the recombinant hemophilia market with its recombinant clotting factor VIII products Recombinante and Advate, but was acquired by Shire in 2016. Sales of Shire's products in 2016 dwarfed those of its competitors in the hemophilia market, including Novo Nordisk, Pfizer, Bioverativ/Sobi and Bayer. Generally speaking, competitive pressures are set to intensify across the forecast period due to the launch of several new products from players and newcomers.

Marchetti concludes: 'GlobalData forecasts that Roche will overtake Shire and become the hemophilia market leader in 2026, with global sales of around $2.5 billion, followed by a recent entrant, Bioverativ, which will have global sales of $1.4 billion in 2025. Overall, it is expected that the ability of companies to endure competition from emicizumab will be linked to their dependence on short-acting clotting factor VIII in their portfolios.'

- Information based on GlobalData's report: PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2026.

GlobalData plc published this content on 19 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 19 July 2017 15:33:07 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
03:56p GLOBALDATA : Taiwan’s Pharmaceutical Market Value to Reach $2.44 billion i..
03:36p GLOBALDATA : The pet insurance market broke the £1bn mark in gross written premi..
09:46a GLOBALDATA : Affluent market, medical tourism to steer best-in line drug deliver..
10/13 GLOBALDATA : Indonesian Pharmaceutical Market Value to Reach $10.11 billion by 2..
10/12 GLOBALDATA : Faster internet and variety of content to galvanise OTT video marke..
10/11 GLOBALDATA : Crohn’s disease market growth to 2026 fuelled by interleukin ..
10/11 GLOBALDATA : Fintech in good times as investments leap, says GlobalData
10/11 GLOBALDATA : Drug development companies in APAC need to raise their game to capi..
10/10 GLOBALDATA : Alzheimer’s disease market set for double-digit growth with f..
10/08 GLOBALDATA : Huawei Jointly Release Network Experience Index White Paper
More news
Financials ( GBP)
Sales 2017 118 M
EBIT 2017 -
Net income 2017 -
Debt 2017 20,5 M
Yield 2017 1,33%
P/E ratio 2017 -
P/E ratio 2018 -
Capi. / Sales 2017 5,19x
Capi. / Sales 2018 -
Capitalization 593 M
Income Statement Evolution
Michael Thomas Danson Chief Executive Officer
Bernard Anthony Cragg Chairman
Simon John Pyper Chief Financial Officer
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RELX N.V.15.35%45 681
RELX15.94%45 656
S&P GLOBAL INC50.47%41 552
EQUIFAX INC.-7.38%13 070